Search

Your search keyword '"Taggart, Melissa"' showing total 386 results

Search Constraints

Start Over You searched for: Author "Taggart, Melissa" Remove constraint Author: "Taggart, Melissa"
386 results on '"Taggart, Melissa"'

Search Results

1. Rectal cancer lexicon 2023 revised and updated consensus statement from the Society of Abdominal Radiology Colorectal and Anal Cancer Disease-Focused Panel.

2. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit

7. Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for Immunoprevention

8. Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa

10. Figure 1 from PIGA Mutations and Glycosylphosphatidylinositol Anchor Dysregulation in Polyposis-Associated Duodenal Tumorigenesis

11. Supplementary Table S3 from PIGA Mutations and Glycosylphosphatidylinositol Anchor Dysregulation in Polyposis-Associated Duodenal Tumorigenesis

12. Supplementary Figure S5 from PIGA Mutations and Glycosylphosphatidylinositol Anchor Dysregulation in Polyposis-Associated Duodenal Tumorigenesis

13. Data from PIGA Mutations and Glycosylphosphatidylinositol Anchor Dysregulation in Polyposis-Associated Duodenal Tumorigenesis

14. Figure 3 from PIGA Mutations and Glycosylphosphatidylinositol Anchor Dysregulation in Polyposis-Associated Duodenal Tumorigenesis

15. Figure 2 from PIGA Mutations and Glycosylphosphatidylinositol Anchor Dysregulation in Polyposis-Associated Duodenal Tumorigenesis

18. Supplemental Figure 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

19. Data from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

20. Supplementary Tables from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

21. TABLE 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

22. Supplemental Figure 2 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

23. Supplementary Figures from Peritoneal Microenvironment Promotes Appendiceal Adenocarcinoma Growth: A Multi-omics Approach Using Patient-Derived Xenografts

24. Supplementary Tables 1-3 from Peritoneal Microenvironment Promotes Appendiceal Adenocarcinoma Growth: A Multi-omics Approach Using Patient-Derived Xenografts

26. Supplementary Materials from Peritoneal Microenvironment Promotes Appendiceal Adenocarcinoma Growth: A Multi-omics Approach Using Patient-Derived Xenografts

27. PIGA mutations and glycosylphosphatidylinositol anchor dysregulation in polyposis-associated duodenal tumorigenesis

28. From Mixed Hyperplastic/Adenomatous Polyp to Sessile Serrated Lesion: A Long and Winding Road for Long and Winding Crypts

30. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma

31. Risk of relapse after surgical resection of localized appendiceal adenocarcinoma.

32. Peritoneal Microenvironment Promotes Appendiceal Adenocarcinoma Growth: A Multi-omics Approach Using Patient-Derived Xenografts

35. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit

36. The Clinical Significance of CEA, CA19-9, and CA125 in Management of Appendiceal Adenocarcinoma

38. Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma

39. Colorectal surveillance outcomes from an institutional longitudinal cohort of lynch syndrome carriers

40. Figure S1 from In Silico Systems Biology Analysis of Variants of Uncertain Significance in Lynch Syndrome Supports the Prioritization of Functional Molecular Validation

41. Supplementary Tables from Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis

42. Supplementary Tables S1-S15 from In Silico Systems Biology Analysis of Variants of Uncertain Significance in Lynch Syndrome Supports the Prioritization of Functional Molecular Validation

43. Data from In Silico Systems Biology Analysis of Variants of Uncertain Significance in Lynch Syndrome Supports the Prioritization of Functional Molecular Validation

44. Supplementary Figures from Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis

45. Supplementary Tables S1-S9 from Mutational Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis

47. Supplementary Figures S1-S15 from Mutational Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis

48. Supplementary Figures + Legend from Optimized Doxorubicin Chemotherapy for Diffuse Large B-cell Lymphoma Exploits Nanocarrier Delivery to Transferrin Receptors

49. Supplementary Material and Methods from The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells

50. Supplementary Figures S1-S6 from The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells

Catalog

Books, media, physical & digital resources